FOX CHASE CANCER CENTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1904-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.foxchase.org
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Metastatic Renal Cell CarcinomaClear-cell Metastatic Renal Cell CarcinomaNeuroendocrine TumorsCarcinoid Tumor
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 86
- Registration Number
- NCT05263050
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Local Consolidative Therapy in Colorectal Cancer
Phase 2
Withdrawn
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Radiation: Local consolidative therapy
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT05062720
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT04827810
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Feasibility Bowel Dysfunction Program After Low Anterior Resection
Not Applicable
Completed
- Conditions
- Rectal CancerLow Anterior Resection
- Interventions
- Procedure: Stoma reversal
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT04733794
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab
Early Phase 1
Withdrawn
- Conditions
- SCLCNSCLC
- Interventions
- Combination Product: MILs™ in Combination with Pembrolizumab
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT04677361
HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT04668768
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer
Not Applicable
Recruiting
- Conditions
- Metastatic Gastric Cancer
- Interventions
- Behavioral: Didactic SessionBehavioral: Comprehensive Geriatric Assessment, including an exploratory analysis to evaluate the use of fitness trackers for evaluation of functional status.
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04618809
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Temple University Hospital, Philadelphia, Pennsylvania, United States
Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening
Not Applicable
Active, not recruiting
- Conditions
- Uterine Cervical Neoplasms
- Interventions
- Behavioral: Community-Based EducationBehavioral: Navigation to ScreeningBehavioral: HPV Self-Sampling
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 797
- Registration Number
- NCT04557423
- Locations
- 🇺🇸
Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, United States
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Phase 2
Active, not recruiting
- Conditions
- Muscle-Invasive Bladder Carcinoma
- Interventions
- Drug: AMVAC + Nivolumab
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 81
- Registration Number
- NCT04506554
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer
Not Applicable
Active, not recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- Radiation: PLDR
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT04452357
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath